Tricuspid valve interventions in 2015.
When the incidence of tricuspid regurgitation is taken into account, along with its impact on functional status and long-term survival, tricuspid regurgitation is currently undertreated. Today, though transcatheter therapy of aortic, mitral- and pulmonic valve disease is well established, interventional treatment of tricuspid valve disease is still in its early stages. Currently, various promising devices are in different stages of development, but it is still too early to clarify which interventional approach in the future might result in functional and clinical success. Similarly, it is yet unclear which type of patient subpopulation will benefit from this type of treatment. Seen in the current context of the overall evolution in the adoption of catheter-based treatments for other types of structural heart disease, the need for and interest in effective interventional treatments for tricuspid regurgitation is growing.